Cover Image, Volume 241, Number 5, May 2026

Meena et al. (Fri,) studied this question.

www.synapsesocial.com/papers/6a0ff327d674f7c03778b9b5 — DOI: https://doi.org/10.1002/jcp.70192

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. A Sampling of Highlights from the Literature· 2024
2. Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology· 2026 · 1 citations
3. Editorial for “Tumor Habitats Based on Multiparametric <scp>MRI</scp> Distinguish Atypical Glioblastoma From Primary Central Nervous System Lymphoma: Imaging‐Pathologic Correlation”· 2025
4. Abstract 3508: Glioblastoma treatment with multifunctional nanodrug inhibiting laminin-411 activates local immune response, increases survival of mice and reveals AI-selected immune molecular pathways· 2026
5. A Sampling of Highlights from the Literature· 2024